It’s called the Amgen Biotech Experience and for a number of teachers across the Piedmont, it could be the key to helping ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...

Genus Capital Management boldly acquired $6.3 million worth of Amgen shares during Q1, signaling confidence in the biotech giant’s trajectory. Amgen continues to attract large institutional investors, ...

The World Child Cancer (WCC) organisation has held its half-year review meeting of 2025 with stakeholders of its Haematology ...

Amgen Inc. closed 14.87% below its 52-week high of $346.85, which the company reached on July 25th.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

Amgen Inc. closed 13.40% below its 52-week high of $346.85, which the company achieved on July 25th.

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

From Amgen's classic double-bottom base in February 1990 until it ultimately topped in the summer of 2000, it increased more ...